West Pharmaceutical Services (WST) Long-Term Deferred Tax (2016 - 2025)
West Pharmaceutical Services' Long-Term Deferred Tax history spans 17 years, with the latest figure at $27.9 million for Q3 2025.
- For Q3 2025, Long-Term Deferred Tax fell 25.8% year-over-year to $27.9 million; the TTM value through Sep 2025 reached $27.9 million, down 25.8%, while the annual FY2024 figure was $26.0 million, 1.17% up from the prior year.
- Long-Term Deferred Tax for Q3 2025 was $27.9 million at West Pharmaceutical Services, down from $29.7 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $99.0 million in Q1 2023 and bottomed at $17.3 million in Q3 2023.
- The 5-year median for Long-Term Deferred Tax is $33.9 million (2024), against an average of $44.2 million.
- The largest annual shift saw Long-Term Deferred Tax skyrocketed 258.74% in 2021 before it plummeted 78.79% in 2024.
- A 5-year view of Long-Term Deferred Tax shows it stood at $48.5 million in 2021, then soared by 35.26% to $65.6 million in 2022, then plummeted by 60.82% to $25.7 million in 2023, then rose by 1.17% to $26.0 million in 2024, then grew by 7.31% to $27.9 million in 2025.
- Per Business Quant, the three most recent readings for WST's Long-Term Deferred Tax are $27.9 million (Q3 2025), $29.7 million (Q2 2025), and $26.0 million (Q1 2025).